摘要
目的 探讨小鼠趋化因子 (mMIP 1α)的重组腺病毒载体 (AdmMIP 1α)体外感染肝癌细胞株Hepa1 6后 ,其体内抗肿瘤活性及其成为肝癌疫苗的可能性。 方法 腺病毒载体体外感染Hepa1 6细胞 ,通过绿色荧光蛋白 (GFP)的表达检测感染效率 ;每天细胞计数 (连续 14d)观察细胞的体外生长曲线 ;取 5× 10 6个修饰后的Hepa1 6细胞接种C5 7BL/ 6小鼠 ,4周后在AdmMIP 1α组未荷瘤小鼠原接种部位的对侧再接种 2× 10 6个野生型Hepa1 6或EL4细胞 ,观察肿瘤大小并作统计学处理。结果 AdmMIP 1α能有效感染靶细胞Hepa1 6 ,感染前、后Hepa1 6的体外生长无明显改变 ;修饰后Hepa1 6细胞的体内成瘤性下降 ;4周后再接种Hepa1 6细胞 ,肿瘤生长速度显著降低 ;而再接种的EL4细胞呈渐进性生长 ,与对照组差异无显著意义。 结论 表达mMIP 1α基因的肝癌细胞的体内成瘤性下降 ,能激发特异性免疫保护反应 ,有可能成为有效的肝癌疫苗。
Objective To observe the in vivo antitumor activity of murine liver tumor vaccine expressing MIP 1α mediated by recombinant adenoviral vector. Methods The infection efficacy was measured by GFP expression 48 hours after infection of Hepa1 6, and the number of cells was counted daily for 14 days. 5×10 6 modified Hepa1 6 cells were inoculated subcutaneously to C57BL/6 mice and the tumor free animals were rechallenged by 2×10 6 wild type Hepa1 6 cells or syngenic EL4 cells four weeks later. The tumor volume was measured twice a week. Results Adenoviral vectors could efficiently infect Hepa1 6 cells in vitro, and the in vitro growth rate of AdmMIP 1α modified Hepa1 6 cells was not affected; however the in vivo tumorigenicity was significantly decreased, compared with that of control vector modified Hepa1 6. Rechallenge of the tumor free mice four weeks after administration of AdmMIP 1α with the parental Hepa1 6 cells resulted in significant inhibition of tumor growth, but there was no significant difference when rechallenged with EL4. Conclusions The liver cancer cells expressing mMIP 1α mediated by recombinant adenoviral vector decrease tumorigenicity and elicit specific immunological protection, and could be used as an effective liver tumor vaccine.
出处
《中华外科杂志》
CAS
CSCD
北大核心
2002年第10期789-791,共3页
Chinese Journal of Surgery
基金
上海市卫生系统百名优秀学科带头人培养基金资助项目 (3 119975 0 3 0 2 10 40 3 )
